BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'

Reuters

Jan 07, 2025

** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O with "buy" rating

** Brokerage says co's experimental drug, ORX750, is "best-in-class" for treating excessive daytime sleepiness (EDS)

** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night

** Notes ORX750 "restored wakefulness at low doses with clean safety" in early-stage trial

** Brokerage says ORX750 demonstrated "higher potency and OX2R selectivity" compared with competitors in early development

** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness

** All 9 brokerages rate stock "buy" or higher; their median PT is $27 - LSEG data

** Stock more than doubled in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501272164"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501272164\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501272164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501272164","market":"us","top_or_hot":-1,"title":"BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'</title></head><body><p>** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals <span>260y.F</span>, <span>CNTA.O</span> with \"buy\" rating</p><p>** Brokerage says co's experimental drug, ORX750, is \"best-in-class\" for treating excessive daytime sleepiness (EDS)</p><p>** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night</p><p>** Notes ORX750 \"restored wakefulness at low doses with clean safety\" in early-stage trial</p><p>** Brokerage says ORX750 demonstrated \"higher potency and OX2R selectivity\" compared with competitors in early development</p><p>** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness</p><p>** All 9 brokerages rate stock \"buy\" or higher; their median PT is $27 - LSEG data</p><p>** Stock more than doubled in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-07 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'</title></head><body><p>** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals <span>260y.F</span>, <span>CNTA.O</span> with \"buy\" rating</p><p>** Brokerage says co's experimental drug, ORX750, is \"best-in-class\" for treating excessive daytime sleepiness (EDS)</p><p>** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night</p><p>** Notes ORX750 \"restored wakefulness at low doses with clean safety\" in early-stage trial</p><p>** Brokerage says ORX750 demonstrated \"higher potency and OX2R selectivity\" compared with competitors in early development</p><p>** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness</p><p>** All 9 brokerages rate stock \"buy\" or higher; their median PT is $27 - LSEG data</p><p>** Stock more than doubled in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nL4N3O30UP:1","article_id":"2501272164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501272164","pubTimestamp":1736249897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O with \"buy\" rating** Brokerage says co's experimental drug, ORX750, is \"best-in-class\" for treating excessive daytime sleepiness ** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night** Notes ORX750 \"restored wakefulness at low doses with clean safety\" in early-stage trial** Brokerage says ORX750 demonstrated \"higher potency and OX2R selectivity\" compared with competitors in early development** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness** All 9 brokerages rate stock \"buy\" or higher; their median PT is $27 - LSEG data** Stock more than doubled in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","CNTA":"Centessa Pharmaceuticals plc","BK4535":"淡马锡持仓","BK4139":"生物科技"},"translate_title":"巴兹-TD Cowen开始对Centessa Pharma进行“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9},"content_text":"BUZZ-TD Cowen starts coverage of Centessa Pharma with 'buy'** TD Cowen initiates coverage of U.S.-listed shares of Centessa Pharmaceuticals 260y.F, CNTA.O with \"buy\" rating** Brokerage says co's experimental drug, ORX750, is \"best-in-class\" for treating excessive daytime sleepiness (EDS)** EDS is a condition where a person feels very sleepy during the day, even after getting enough sleep at night** Notes ORX750 \"restored wakefulness at low doses with clean safety\" in early-stage trial** Brokerage says ORX750 demonstrated \"higher potency and OX2R selectivity\" compared with competitors in early development** OX2R, also known as orexin receptor 2, is a protein in the brain that helps control sleep and wakefulness** All 9 brokerages rate stock \"buy\" or higher; their median PT is $27 - LSEG data** Stock more than doubled in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}